MiroliverELAP® for the Treatment of Acute Liver Failure: a Phase 1 Trial

ID#: NCT06285253

Age: 18 - 80 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 1

Recruitment Status: Recruiting

Start Date: October 01, 2024

End Date: February 28, 2025

Contact Information:
Joshua Carlson
612-670-5981
M. Mason Macenski, PhD
612-378-2612
Summary: The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.
Eligibility:

Inclusion Criteria:

1. 18 years to 80 years old at the time of signing the informed consent

2. Subject must:

1. be deemed competent to consent by an independent qualified practitioner, or

2. have consent given by a Legally Authorized Representative

3. Be diagnosed with acute liver failure as defined as:

1. INR ≥ 2.5, and

2. Hepatic Encephalopathy Grade II-III (West Haven Criteria), and

3. Less than 4 weeks (28 days) of disease duration

4. Subject is not a candidate for liver transplant and will not become a candidate in the event of worsening conditions. Exclusion Criteria

1. Underlying chronic liver disease, including:

1. Acute-on-chronic liver disease

2. Acute alcoholic-associated hepatitis

3. Cirrhosis

2. Grade IV West Haven Encephalopathy Criteria

3. Previous liver transplant

4. Currently requires chronic hemodialysis (CRRT or other forms of continuous renal replacement are allowed).

5. Uncontrolled- documented infection, hypotension or refractory shock. This is defined as a need for a single vasopressor, or combination of vasopressors, that exceed a norepinephrine equivalent of 0.3 mcg/kg/min.

6. Liver injury due to trauma

7. Any current liver cancer

8. Currently on medications with a narrow therapeutic index

9. Platelet count < 40,000 μL

10. If the subject is intubated and has an acute lung injury

11. Experiencing a bleeding event, defined as:

1. Active gastrointestinal or other overt bleeding event, or

2. Hemoglobin drop > 3g/dL within the past 24 hours, or

3. Received ≥ 3 units of red blood cell transfusion within the past 24 hours

12. Female that is currently pregnant, planning to be pregnant, or currently breastfeeding

13. Refusal to receive blood products
Find a Clinical Trial Find Cancer Clinical Trials